Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | KYNU | Q16719 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2218264 | 1.00 | ALDH1A1 (0.53) | ALDH1A1ALOX15CYP3A4TSHRMEN1 | |
| SCHEMBL1712911 | 0.91 | ACE (0.53) | CTSLCTSBCTSS | |
| SCHEMBL1712913 | 0.91 | ACE (0.53) | CTSLCTSBCTSS | |
| SCHEMBL11026131 | 0.85 | CYP1A2 (0.49) | HDAC1HDAC6 | |
| SCHEMBL11026130 | 0.85 | CYP1A2 (0.49) | HDAC1HDAC6 | |
| SCHEMBL7151822 | 0.81 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4TSHRMEN1 | |
| SCHEMBL329686 | 0.81 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4TSHRMEN1 | |
| SCHEMBL3603477 | 0.81 | CYP3A4 (0.51) | ALDH1A1ALOX15CYP3A4TSHRMEN1 | |
| SCHEMBL3603473 | 0.81 | CYP3A4 (0.51) | ALDH1A1ALOX15CYP3A4TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL7928050 | 0.80 | ALDH1A1 (0.72) | ALDH1A1ALOX15CYP3A4TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102171246-A | Novel octapeptide compounds derived from somatostatin and therapeutic uses thereof | IPSEN PHARMA SAS | 2011-08-31 | — | — | CN | disclosed |
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | SSTR5, SSTR1, SSTR3 | ALDH1A1 3810/4885ALOX15 1619/4885CYP3A4 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.